Question explored with the scientific record
Does NAD+ tablets increase cell youth and longevity?
The short version: NAD+ pills reliably raise a lab number in your blood. No trial has shown they make you younger or help you live longer.
The evidence here is about NMN, a precursor the body converts to NAD+, not NAD+ tablets themselves. Oral NMN does raise blood NAD+ in middle-aged and older adults [1][4][5]. That is a lab value, not a health outcome. The trials that measured real function mostly found nothing: 24 weeks of high-dose NMN did not improve hearing, grip strength, gait speed, or walking distance in healthy older adults [5]. A 12-week trial found no significant muscle mass or metabolic change [3]. A meta-analysis of eight NMN trials found no benefit on cholesterol or blood sugar [6]. The one "biological age" result was a commercial blood calculator, and NMN only prevented the placebo group's score from rising, it did not lower anyone's age [4].
| Trial | Dose / length | Real outcome |
|---|---|---|
| Older men [3] | 250 mg, 12 wk | Gait and grip trended up, muscle mass flat |
| Middle-aged [4] | 300-900 mg, 60 days | Walking distance up, HOMA-IR rose at high dose |
| Older adults [5] | 1250 mg, 24 wk | No hearing or physical gains |
| Meta-analysis [6] | 250-2000 mg | No lipid or glucose benefit |
Safety is short-term only. Trials ran 60 days to 24 weeks [4][5]. One high-dose participant stopped for elevated liver enzymes [5]. Longevity has never been tested in humans. The mouse lifespan signal came from a different compound, NR, not NAD+ pills [2]. Nobody has run a trial with death or disease as the endpoint.
My call: skip it for longevity. It moves a biomarker, not your healthspan, and the long-term safety data does not exist. Confidence: moderate.
Sources used 6
-
EFFICACY OF NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION (NMN) IN BLOOD NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) FOR ANTI-AGING IN ADULTS: A SYSTEMATIC REVIEW
A systematic review of six RCTs found that oral NMN supplementation (250–900 mg/day for 10–12 weeks) significantly increased blood NAD concentrations in adults, with only mild adverse effects, supporting its potential anti-aging benefit.
DOI: 10.61841/gyj2gr52 -
NAD+ biosynthesis, aging, and disease
This narrative review argues that age-related NAD+ decline, driven by reduced NAMPT biosynthesis and increased consumption by PARPs/CD38, impairs sirtuin activity and contributes to age-associated disease, and that NMN or NR supplementation can restore NAD+ and mitigate decline.
DOI: 10.12688/f1000research.12120.1 -
Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men
In healthy older men, 250 mg/day oral NMN for 12 weeks raised whole-blood NAD+ and related metabolites, was well tolerated, and nominally improved gait speed and left grip strength but not muscle mass.
DOI: 10.1038/s41514-022-00084-z -
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
In a 60-day double-blind dose-ranging trial in 80 healthy middle-aged adults, oral NMN (300-900 mg/day) raised blood NAD, improved walking distance, and prevented biological-age increase while being safe, although HOMA-IR rose in the 600 and 900 mg groups.
DOI: 10.1007/s11357-022-00705-1 -
Sustained NAD⁺ augmentation by high-dose nicotinamide mononucleotide supplementation in older adults: a 24-week randomized, double-blind, placebo-controlled trial
In healthy older adults, 24 weeks of 1250 mg/day NMN robustly raised blood NAD⁺ and related metabolites but did not improve hearing, physical performance, or other physiological outcomes.
DOI: 10.1038/s41514-026-00482-7 -
Clinical evidence for the use of NAD+ precursors to slow aging
Oral NAD+ precursor supplementation reliably raises blood NAD+ and is generally safe in middle-aged and older adults, but clinical benefits on cardiovascular, metabolic, muscle and cognitive outcomes remain inconsistent and unproven.
DOI: 10.70401/geromedicine.2025.0008